» Articles » PMID: 15016750

Incidence and Management of Malignant Digestive Endocrine Tumours in a Well Defined French Population

Overview
Journal Gut
Specialty Gastroenterology
Date 2004 Mar 16
PMID 15016750
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Little is known about the epidemiology of malignant digestive endocrine tumours. The aim of this study was to report on their incidence and management in a well defined population.

Methods: Data were obtained from the population based Digestive Cancer Registry of Burgundy (France) over a 24 year period. Incidence rates were calculated by sex, age groups, and period of diagnosis. Treatment and stage at diagnosis were also investigated. Prognosis was determined using crude and relative survival rates. A multivariate relative survival analysis was performed.

Results: Between 1976 and 1999, 229 cases were recorded. Age standardised incidence rates were 0.76/100,000 for men and 0.50/100,000 for women. They increased over time in both sexes. The resectability rate was 74.1%. Among recorded cases, 26.6% did not extend beyond the organ, 20% had lymph node metastases, and 53.3% had visceral metastases or were unresectable. There was no improvement in the resection rate or in the stage at diagnosis over the study period. The overall relative survival rate was 66.9% at one year, 50.4% at five years, and 40.6% at 10 years. Stage at diagnosis, age at diagnosis, and subsite were independent significant prognostic factors.

Conclusions: Although their incidence is increasing, malignant digestive endocrine tumours remain a rare cancer, representing 1% of digestive cancers. Stage at diagnosis and prognosis at a population level are worse than those reported in hospital series. In the short term, new therapeutic possibilities represent the best way to improve their prognosis.

Citing Articles

Extremely rare mucinous adenocarcinoma of the small bowel causing bilateral metastatic Kukenberg tumors of the ovaries: A case report.

Zhu L, Liu Y, Chen S, Yang G, Wang C Medicine (Baltimore). 2024; 103(44):e40397.

PMID: 39496016 PMC: 11537637. DOI: 10.1097/MD.0000000000040397.


Evaluation of a blood miRNA/mRNA signature to follow-up Lu-PRRT therapy for G1/G2 intestinal neuroendocrine tumors.

Jacques V, Dierickx L, Texier J, Brillouet S, Courbon F, Guimbaud R Front Endocrinol (Lausanne). 2024; 15:1385079.

PMID: 38948517 PMC: 11212830. DOI: 10.3389/fendo.2024.1385079.


Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.

Hinterleitner M, Pfeiffer R, Trautwein N, Sipos B, Singer S, Nadalin S Front Endocrinol (Lausanne). 2024; 14:1285529.

PMID: 38260136 PMC: 10800837. DOI: 10.3389/fendo.2023.1285529.


Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center.

Coelho S, Costa C, Santos A, Souteiro P, Oliveira J, Oliveira J Endocr Oncol. 2023; 2(1):32-41.

PMID: 37435456 PMC: 10259287. DOI: 10.1530/EO-22-0043.


Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers.

Chen X, Zhou R, Li Y, Qu X, Qu Y, Li W Front Immunol. 2022; 13:1046513.

PMID: 36531985 PMC: 9755197. DOI: 10.3389/fimmu.2022.1046513.


References
1.
Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou J . Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998; 43(3):422-7. PMC: 1727238. DOI: 10.1136/gut.43.3.422. View

2.
Watson R, Johnston C, OHARE M, ANDERSON J, Wilson B, Collins J . The frequency of gastrointestinal endocrine tumours in a well-defined population--Northern Ireland 1970-1985. Q J Med. 1989; 72(267):647-57. View

3.
Newton J, Swerdlow A, dos Santos Silva I, Vessey M, Grahame-Smith D, Primatesta P . The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer. 1994; 70(5):939-42. PMC: 2033547. DOI: 10.1038/bjc.1994.424. View

4.
Sobin L, FLEMING I . TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997; 80(9):1803-4. DOI: 10.1002/(sici)1097-0142(19971101)80:9<1803::aid-cncr16>3.0.co;2-9. View

5.
Berge T, Linell F . Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A. 1976; 84(4):322-30. View